In the last trading session, 1.77 million iBio Inc (NASDAQ:IBIO) shares changed hands as the company’s beta touched 0.95. With the company’s per share price at $0.91 changed hands at -$0.07 or -7.14% during last session, the market valuation stood at $15.11M. IBIO’s last price was a discount, traded about -657.14% off its 52-week high of $6.89. The share price had its 52-week low at $0.64, which suggests the last value was 29.67% up since then.
Analysts gave the iBio Inc (IBIO) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended IBIO as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. iBio Inc’s EPS for the current quarter is expected to be -0.34.
iBio Inc (NASDAQ:IBIO) trade information
Instantly IBIO was in red as seen at the end of in last trading. With action 11.39%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -62.67%, with the 5-day performance at 11.39% in the green. However, in the 30-day time frame, iBio Inc (NASDAQ:IBIO) is 10.18% up.
The consensus price target for the stock as assigned by Wall Street analysts is 3.6, meaning bulls need an upside of 74.72% from its current market value. According to analyst projections, IBIO’s forecast low is 3.6 with 3.6 as the target high. To hit the forecast high, the stock’s price needs a -295.6% plunge from its current level, while the stock would need to soar -295.6% for it to hit the projected low.
iBio Inc (IBIO) estimates and forecasts
Year-over-year growth is forecast to reach 48.15% up from the last financial year.
Consensus estimates given by 3 financial analysts project the company’s revenue in the current quarter to hit an average of 66.67k. The company’s revenue for the corresponding quarters a year ago was 175k. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -61.90%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 57.55%. The 2025 estimates are for iBio Inc earnings to increase by 56.08%.
IBIO Dividends
iBio Inc is expected to release its next quarterly earnings report in July.
IKARIAN CAPITAL, LLC holds the second largest percentage of outstanding shares, with 6.9576% or 0.6 million shares worth $1.27 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund and Fidelity Concord Street Trust-Fidelity Extended Market Index Fund . With 138.4 shares estimated at $0.13 million under it, the former controlled 0.84% of total outstanding shares. On the other hand, Fidelity Concord Street Trust-Fidelity Extended Market Index Fund held about 0.33% of the shares, roughly 54.73 shares worth around $50046.0.
